Quarterly Results
ACHV Earnings Forecast
Looking ahead, ACHV remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of -0.27.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been No Change by 0%, while EPS estimates have been Revise Upward by 4.61%. For the upcoming Q3 2026, revenue estimates have been adjusted Revise Upward by 14.65% . These revisions correlate with a 58.55% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ACHV long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency:

No data
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how ACHV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ACHV sees a +1.58% change in stock price 10 days leading up to the earnings, and a +2.58% change 10 days following the report. On the earnings day itself, the stock moves by -0.55%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -3.16% on the day following the earnings release and then changed by -18.14% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of ACHV's latest earnings report for FY2025Q3?
ACHV reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 0.00 against an estimate of 17.70M, resulting in a 0% surprise. The EPS was -0.28, surpassing the expected -0.24 by -16.67% . The stock experienced a -3.85% price change on the earnings day and a -3.25% change over the next five days, reflecting market reactions to the results.
How did ACHV's stock price react after the FY2025Q3 earnings release?
Following ACHV's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -3.85% on the day of the release. Over the subsequent five days, it saw a -3.25% change. Historically, ACHV's stock price tends to shift by an average of +1.58% in the 10 days leading up to earnings and +2.58% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for ACHV for undefined?
For , analysts estimate ACHV’s annual revenue to reach undefined, while the EPS is projected at -0.27. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 14.65% over the past three months, indicating analyst expectation in the company’s performance.
How does ACHV's stock price correlate with earnings forecast revisions?
The correlation between ACHV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were No Change by 0%, while EPS estimates moved Revise Upward by 14.65% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from ACHV's next earnings report?
Based on historical trends, ACHV's stock price typically moves by +1.58% in the 10 days before its earnings and +2.58% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.27 and revenue of undefined.
What is the sentiment in Achieve Life Sciences Inc (ACHV) Q3 2025 Earnings Call Summary?
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.

